1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
ILSUNG IS CO., LTD.

ILSUNG IS CO., LTD.

KKRX:003120
21,500.00
KRW
-300.00
(-1.38%)
790.55EPS
24.01P/E
135.94BMarket Cap
ILSUNG IS CO., LTD.
KRX:003120
(Korea Stock Exchange)

Recent

price

21,500.00

P/E

ratio

24.01

div

yld

0.01%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
8,062.58
9,377.4
11,178.78
9,280.17
9,349.83
9,189.88
10,039.32
9,977.44
9,176.11
7,002.47
5,295.33
5,490.87
1,638.1
11,159.57
10,125.49
9,374.9
9,302.33
Revenue per Share
740.2
4,824.44
5,281
1,175.4
600.4
14,713
449
391.2
438.4
971.8
420
-178.4
2,906.4
-2,994
1,921
170
790.55
Basic EPS, GAAP
1,644.15
991.87
-1,737.92
581.71
463.54
475.22
-5,027.68
1,236.52
2,048
455.38
-425.19
-901.97
-2,713.63
-7,034.56
-2,397.43
248.71
-864.23
Free Cash Flow per Basic Share
107.65
103.19
100.67
60.67
49.99
100
149.98
149.99
150
145.78
150.03
150.07
30.77
4,240.12
1,495.91
993.85
2.57
Dividend per Share
50,519.55
47,737.62
46,478.28
48,035.7
48,919.54
47,380.59
47,642.28
48,047.91
48,272.48
45,051.07
45,310.12
45,105.86
60,559.13
56,157.87
56,507.2
53,943.34
53,025.3
Book Value per Share
50,436.41
47,555.01
46,322
47,910.77
48,813.25
47,325.12
47,609
48,015.45
48,223.72
45,011.53
45,273.75
44,855.62
60,250.19
55,808.95
56,105.47
53,576.8
52,395.36
Tangible Book Value per Share
9
7
7
7
7
7
7
7
7
7
8
8
37
7
7
7
7
Basic Weighted Avg Shares
68,595
68,192
77,161
62,807
62,829
61,745
67,463
67,043
61,653
48,412
40,601
42,090
61,248
78,053
69,018
64,292
65,216
Sales/Revenue/Turnover
6.54
6.21
1.71
2.18
3.87
4.19
3.64
3.86
3.66
-2.6
-4.8
-4.27
2.18
-32.35
-4.7
-9.58
-7.53
Operating Margin (%)
3,392
3,240
3,281
3,202
2,812
2,761
3,022
3,227
3,013
3,085
3,059
3,074
3,053
3,086
3,619
3,323
3,241
Depreciation Expense
6,297
35,083
36,452
7,955
4,035
98,854
3,017
2,629
2,946
6,719
3,220
-1,368
108,669
-20,941
13,094
1,166
5,542
Net Income, GAAP
30.6
25.32
24.52
27.52
48.97
24.55
39.5
42.63
35.78
26.81
27.09
- -
23.63
- -
- -
58.77
32.93
Effective Tax Rate (%)
9.18
51.45
47.24
12.67
6.42
160.1
4.47
3.92
4.78
13.88
7.93
-3.25
177.43
-26.83
18.97
1.81
8.5
Profit Margin (%)
34,181
22,956
26,599
128,711
133,829
262,743
261,053
263,299
263,517
254,125
246,424
259,238
322,046
259,051
260,100
254,522
249,589
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
127
130
10
182
120
82
79
66
LT Debt
379,096
331,705
318,059
322,744
328,683
318,343
320,101
322,826
324,335
345,489
347,476
345,910
448,995
382,754
385,135
386,345
379,770
Total Equity
0.89
0.91
0.3
0.31
0.38
0.57
0.44
0.46
0.45
-0.27
-0.41
- -
0.25
- -
- -
-0.66
-0.87
Return on Invested Capital (%)
1.81
9.8
11.16
2.48
1.24
30.56
0.95
0.82
0.91
2.01
0.93
- -
27.33
- -
- -
0.31
1.47
Return on Capital (%)
1.82
9.87
11.22
2.48
1.24
30.56
0.95
0.82
0.91
2.01
0.93
-0.39
27.34
-5.04
3.41
0.3
1.47
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
54
59
57
LT Borrowings
- -
- -
- -
LT Finance Leases
79
81
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
156,133
157,565
135,936

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
269,977
271,172
262,444
Cash, Cash Equivalents & STI
225,928
226,136
211,967
Accounts Receivable, Net
16,278
16,510
16,154
Inventories
26,498
26,283
24,608
Total Current Liabilities
15,455
22,162
12,855
Payables & Accruals
- -
- -
- -
ST Debt
54
59
57
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.45%
3.11%
0.31%
Free Cash Flow
-24.7%
250.16%
-110.44%
Net Income, GAAP
-858.36%
-1,712.38%
-91.1%
Sales/Revenue/Turnover
2.12%
11.64%
-6.85%
Total Cash Common Dividend
- -
- -
-33.16%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,986
17,143
19,019
16,870
69,018
2025
16,621
16,255
16,762
14,654
64,292
2026
16,709
17,091
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-98
-62
1,411
669.6
1,921
2025
226
-605
50.04
498.57
170
2026
220.23
30
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,495.91
2025
- -
- -
2.64
- -
993.85
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ilsung Is Co., Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers a broad portfolio of generic and branded medications, including penicillin antibiotics; contrast mediums such as iohexol and iopamidol formulations (Rayhexol Inj., Raypam Inj.); digestive drugs; cardiovascular agents; antihistamines; anti-diabetics; bone disease drugs; analgesics; muscle relaxants; anesthetics including sevoflurane (Sevoprane Inhalation Solution); skin disease drugs; psychiatry drugs such as nortriptyline hydrochloride (Sensival); antivirals; antipyretics; circulatory system drugs; anti-coagulants; probiotics; vaccines; medical equipment; diabetes treatments; osteopathic medicines; anti-emetics; respiratory treatments; adrenal cortical steroids; and neuromuscular blockers/central muscle relaxants. Ilsung Is distributes its products through wholesalers, hospitals, pharmacies, and other channels while also providing consignment manufacturing services (CMO) particularly for antibiotics. Founded in 1954 and headquartered at 9 Wonhyo-ro 84-gil, Yongsan-gu, Seoul, South Korea, the company primarily serves domestic markets with select exports to regions including Georgia, Japan, Mongolia, and Pakistan, and maintains partnerships with global firms such as GSK, Abbott, Ono, and Teijin for in-licensing. In April 2024, Ilsung Pharmaceuticals Co., Ltd. changed its name to Ilsung Is Co., Ltd., reflecting a strategic rebranding amid ongoing focus on core therapeutic areas like antibiotics, cardiovascular, anesthetics, and contrast media, with expansions into gastrointestinal, central nervous system, and other segments; the firm reported earnings for Q1 2025 ended March 31, underscoring stable operations under CEO Suk-Keun Yoon.